Abstract
MicroRNAs are small noncoding RNAs that have emerged as important regulators of many biological and pathological processes, including those relevant to the development of the heart and cardiovascular disease. Several recent studies using genetic models and profiling of microRNAs have established the important role of these novel molecules in a number of conditions of the heart. These studies have led to a flurry of research focussing on the identification of new therapeutic targets for the treatment of cardiac disease, as well as the identification of potential biomarkers for early diagnosis of heart disease. These early reports have stimulated much interest in microRNAs and indeed other non-coding RNAs in the broader context of cardiovascular disease. This work has been further investigated as a result of ease with which the levels of these molecules can be modulated both in vitro but also in animal disease models. Furthermore, a number of studies have specifically looked at the prognostic potential of these microRNAs as biomarkers of cardiovascular disease. This review is focused on highlighting some of the novel aspects of recent research in the area of the development of new therapeutics and better diagnostics for cardiovascular disease.
Keywords: microRNA, cardiovascular disease, biomarkers.
Current Pharmaceutical Design
Title:microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease
Volume: 20 Issue: 14
Author(s): Shinji Hagiwara, Phillip Kantharidis and Mark E. Cooper
Affiliation:
Keywords: microRNA, cardiovascular disease, biomarkers.
Abstract: MicroRNAs are small noncoding RNAs that have emerged as important regulators of many biological and pathological processes, including those relevant to the development of the heart and cardiovascular disease. Several recent studies using genetic models and profiling of microRNAs have established the important role of these novel molecules in a number of conditions of the heart. These studies have led to a flurry of research focussing on the identification of new therapeutic targets for the treatment of cardiac disease, as well as the identification of potential biomarkers for early diagnosis of heart disease. These early reports have stimulated much interest in microRNAs and indeed other non-coding RNAs in the broader context of cardiovascular disease. This work has been further investigated as a result of ease with which the levels of these molecules can be modulated both in vitro but also in animal disease models. Furthermore, a number of studies have specifically looked at the prognostic potential of these microRNAs as biomarkers of cardiovascular disease. This review is focused on highlighting some of the novel aspects of recent research in the area of the development of new therapeutics and better diagnostics for cardiovascular disease.
Export Options
About this article
Cite this article as:
Hagiwara Shinji, Kantharidis Phillip and Cooper E. Mark, microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease, Current Pharmaceutical Design 2014; 20 (14) . https://dx.doi.org/10.2174/13816128113199990495
DOI https://dx.doi.org/10.2174/13816128113199990495 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
UCLA’s Molecular Screening Shared Resource: Enhancing Small Molecule Discovery with Functional Genomics and New Technology
Combinatorial Chemistry & High Throughput Screening Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment
Current Medicinal Chemistry Alzheimer’s Disease And Type 2 Diabetes: Exploring The Association To Obesity And Tyrosine Hydroxylase
CNS & Neurological Disorders - Drug Targets Pathophysiology and Therapeutics of Cardiovascular Disease in Metabolic Syndrome
Current Pharmaceutical Design Clinical Applicability of Conditioning Techniques in Ischemia-Reperfusion Injury: A Review of the Literature
Current Cardiology Reviews Dyslipidemia Treatment and Cardiovascular Disease in the Renal Patient
Current Pharmaceutical Design Pharmacophore-based Screening for Identification of Human Acyl-CoA Cholesterol Acyltransferase Inhibitors: An In-silico Study
Letters in Drug Design & Discovery Erythropoietin: New Horizon in Cardiovascular Medicine
Recent Patents on Cardiovascular Drug Discovery Choice of Treatment with Antidepressants: Influencing Factors
Current Pharmaceutical Design Editorial [Hot Topic: Efficient Strategies for Signalling Pathway Mining (Guest Editors: Qingfeng Chen & Baoshan Chen)]
Current Protein & Peptide Science Clinical Assessment of Central Blood Pressure
Current Hypertension Reviews The Etiology of Hypertension in the Metabolic Syndrome Part Two: The Gene-Environment Interaction
Current Vascular Pharmacology Plasma Steroid Level Measured Using Modern Separation Techniques as Biomarkers in Biological Diagnostics
Current Pharmaceutical Analysis Cytochrome P450 2C8 and Drug Metabolism
Current Topics in Medicinal Chemistry Efficacy of Chemopreventive Agents in Mouse Mammary Gland Organ Culture (MMOC) Model: A Comprehensive Review
Current Medicinal Chemistry Oxidative Stress and Mitochondrial Dysfunction in Type 2 Diabetes
Current Pharmaceutical Design Vasorelaxant and Antihypertensive Effects of <i>Mentha pulegium</i> L. in Rats: An In vitro and In vivo Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets Evaluation of Post-Surgical Cognitive Function and Protein Fingerprints in the Cerebro-Spinal Fluid Utilizing Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass-Spectrometry (SELDI-TOF MS) After Coronary Artery Bypass Grafting: Review of Proteomic Analytic Tools and Introducing a New Syndrome
Current Medicinal Chemistry Targeted Drugs and Nanomedicine: Present and Future
Current Pharmaceutical Design Significance of Pharmacogenetics and Pharmacogenomics Research in Current Medical Practice
Current Drug Metabolism